compounded semaglutide fda warning november 2025 Important Update: Changes to Availability FDA and Novo Nordisk Warned
Description
Weight loss isnt just about willpower
SYMLIN may cause bruising, swelling, or itching at the injection site
Aronne said gastrointestinal adverse events were more common with semaglutide than nimacimab, with nimacimab having similar rates of gastrointestinal adverse events as the placebo group
Constipation is very common and can lead people to stop taking these drugs, and its largely manageable
Weight loss extends beyond appearance
The gap between the ad and reality is significant
